Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Nilotinib induced deeper molecular responses than continued imatinib in patients with minimal residual disease on long-term imatinib. These deeper responses may enable more patients to benefit from treatment-free remission trials.

authors

Hughes, Timothy P
Lipton, Jeffrey H
Spector, Nelson
Cervantes, Francisco
Pasquini, Ricardo
Clementino, Nelma Cristina D
Dorlhiac Llacer, Pedro Enrique
Schwarer, Anthony P
Mahon, Francois-Xavier
Rea, Delphine
Branford, Susan
Purkayastha, Das
Collins, LaTonya
Szczudlo, Tomasz
Leber, Brian

status

published

publication date

July 31, 2014

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Adult (MeSH)
Aged (MeSH)
Aged, 80 and over (MeSH)
Benzamides (MeSH)
Drug Substitution (MeSH)
Female (MeSH)
Fusion Proteins, bcr-abl (MeSH)
Humans (MeSH)
Imatinib Mesylate (MeSH)
Immunology (Science Metrix)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (MeSH)
Male (MeSH)
Middle Aged (MeSH)
Piperazines (MeSH)
Protein Kinase Inhibitors (MeSH)
Pyrimidines (MeSH)
Time Factors (MeSH)

published in

Blood Journal